HDAC6, at the Crossroads Between Cytoskeleton and Cell Signaling by Acetylation and Ubiquitination

Total Page:16

File Type:pdf, Size:1020Kb

HDAC6, at the Crossroads Between Cytoskeleton and Cell Signaling by Acetylation and Ubiquitination Oncogene (2007) 26, 5468–5476 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination C Boyault, K Sadoul, M Pabion and S Khochbin INSERM, U823, Equipe Epige´ne´tique et Signalisation Cellulaire, Institut Albert Bonniot, Universite´ Joseph Fourier, Domaine de la Merci, Grenoble, La Tronche Cedex, France Histone deacetylase 6 (HDAC6)is a unique enzyme with et al., 2005). Moreover, it is now clear that acetylation is specific structural and functional features. It is actively or not an exclusive modification of nuclear proteins, since stably maintained in the cytoplasm and is the only many cytoplasmic proteins, including a significant member, within the histone deacetylase family, that subset of mitochondrial proteins, have recently been harbors a full duplication of its deacetylase homology shown to bear lysine acetylation (Cohen et al., 2004; region followed by a specific ubiquitin-binding domain at Dihazi et al., 2005; Iwabata et al., 2005; Kovacs et al., the C-terminus end. Accordingly, this deacetylase func- 2005; Hallows et al., 2006; Kim et al., 2006; Schwer tions at the heart of a cellular regulatory mechanism et al., 2006). The regulation of these acetylations and capable of coordinating various cellular functions largely the determination of their functional significance relying on the microtubule network. Moreover, HDAC6 now constitute a real challenge for biologists. In fact, action as a regulator of the HSP90 chaperone activity while the list of cytoplasmic acetylated proteins is adds to the multifunctionality of the protein, and allows us rapidly growing, basic information on the involved to propose a critical role for HDAC6 in mediating and enzymatic machinery, HATs and HDACs, as well as on coordinating various cellular events in response to their functions, is still missing. different stressful stimuli. The identification of HDAC6 as the first HDAC Oncogene (2007) 26, 5468–5476; doi:10.1038/sj.onc.1210614 actively maintained in the cytoplasm (Verdel et al., 2000) opened the way for the identification of its sub- Keywords: microtubule; actin; HSP90; virus; aggresome; strates and cellular functions controlled by its catalytic transcription activity in this compartment. Further analyses of HDAC6 functions revealed the involvement of the protein in cellular processes dependent and independent of its catalytic activity. Indeed, the discovery of an Introduction ubiquitin-binding domain in HDAC6 (Seigneurin-Berny et al., 2001) led to the unraveling of its participation in Protein lysine acetylation is now emerging as a widely cellular functions depending on cell signaling through occurring post-translational modification and constitu- protein ubiquitination (Kawaguchi et al., 2003; Boyault tes a genuine cellular signaling system involved in the et al., 2006). HDAC6 therefore appears as a protein control of various functions in different cellular functioning at the crossroads between at least two compartments (reviewed in Kouzarides, 2000; Sterner cellular signaling systems, respectively, involving protein and Berger, 2000; Caron et al., 2003; Yang, 2004; lysine acetylation and ubiquitination. Glozak et al., 2005). Originally, lysine acetylation, HDAC6 is not the only cytoplasmic deacetylase. mainly that of histones and transcription factors, was In fact, early investigations showed that under specific regarded as a powerful mean of gene expression circumstances, other HDACs of different classes regulation. Rapid progress in the discovery and func- could also be found in the cytoplasm. However, their tional analysis of an increasing number of nuclear cytoplasmic functions remain elusive and except for enzymes involved in protein lysine acetylation and SIRT2, a class III HDAC member (North et al., 2003), deacetylation, histone acetyltransferases (HATs) and none of the HDAC6 activities seems to be shared by histone deacetylases (HDACs), respectively, have these enzymes (Hubbert et al., 2002; Matsuyama et al., demonstrated that these enzymes, independently of 2002). Among them, HDAC10 deserves a special atten- transcription, can control some of the basic cellular tion since it is the closest relative of HDAC6. Indeed, processes such as protein stability (reviewed in Caron the HDAC10 catalytic domain shows the highest homology to those of HDAC6 and, moreover, its pseudo-duplication is reminiscent of HDAC6 cata- Correspondence: Dr S Khochbin, INSERM, U823, Equipe Epige´ ne´ - lytic domain duplication. This characteristic of HDAC10 tique et Signalisation Cellulaire, Institut Albert Bonniot, Universite´ Joseph Fourier, Domaine de la Merci, Grenoble, La Tronche Cedex, justifies a close examination of the known HDAC10 France. activities in the light of data available on HDAC6 E-mail: [email protected] functions. HDAC6, a coordinator of cell responses to stressful stimuli C Boyault et al 5469 This review will therefore essentially consider the HDAC activity of HDAC6 relies either on the integrity important body of data now available on HDAC6 since of both HDAC domains (Zhang et al., 2003, 2006) or its discovery in 1999 (Grozinger et al., 1999; Verdel and is mediated by its second catalytic domain (Zou et al., Khochbin, 1999), aiming to draw a synthetic scheme of 2006). The discovery of a-tubulin as an HDAC6 sub- its cellular functions and highlight its possible involve- strate (Hubbert et al., 2002; Matsuyama et al., 2002; ment in human pathologies. Zhang et al., 2003) allowed researchers to also include acetylated tubulin in these assays (Haggarty et al., 2003; Zhang et al., 2003, 2006; Zou et al., 2006). Here again, some of the investigators found that the integrity Domain organization and structural features of HDAC6 of both HDAC6 catalytic domains was indispensable for the whole tubulin deacetylase (TDAC) activity of HDAC6 is the only member of the cellular deacetylase the enzyme (Zhang et al., 2003, 2006), whereas others family containing a full duplication of the large class I/II showed that the whole TDAC activity could be HDAC-homology domain (Figure 1), first revealed in attributed to the second domain (Haggarty et al., the mouse HDAC6 (Verdel and Khochbin, 1999) and 2003; Zou et al., 2006). then in its human ortholog (Grozinger et al., 1999). This Additional investigations revealed the existence of feature could be considered as a unique signature other structural requirements for an efficient HDAC allowing the identification of HDAC6 orthologs in and TDAC activity of HDAC6. Indeed, the spacer other species including invertebrates, Drosophila mela- region between the two catalytic domains of the protein nogaster and Caenorhabditis elegans as well as in plants was found to play a crucial role in the total activity of such as Arabidopsis thaliana (Barlow et al., 2001; HDAC6, and amino acid addition or deletion in this reviewed in Yang and Gregoire, 2005). region dramatically affected the TDAC activity of The conservation of the double catalytic domain HDAC6. The HDAC activity of HDAC6 seemed, organization during evolution strongly argues in favor however, to be less dependent on the length of this of a critical role for this domain duplication in HDAC6 linker region than its TDAC activity (Zhang et al., functions and prompted the investigators to uncover 2006). These studies also evidenced an important role its role in the whole deacetylase activity of the enzyme. for a conserved region present in HDACs and some One obvious way to tackle this issue consisted in the HATs, known as substrate recognition site or Esa1- measurement of the deacetylase activity of HDAC6 Rpd3 (ER) motif (Adachi et al., 2002). Both HDAC and mutants containing inactivating mutations in each TDAC activities of HDAC6 rely on this motif present in domain individually. Unexpectedly, these experiments each domain, but the ER in the second HDAC domain generated conflicting results. The first attempt showed has a particularly critical role in TDAC activity of the that each domain possessed an independent catalytic enzyme (Zhang et al., 2006). activity (Grozinger et al., 1999). This result was, Overall, despite these contradictory data, the second however, challenged by other groups showing that the domain of HDAC6 seems to have a determinant role in at least the total TDAC activity of the enzyme (Haggarty et al., 2003; Zhang et al., 2006; Zou et al., HDAC6 2006). NES SE14 In addition to HDAC6 catalytic activities, the control of its intra-cellular localization was also found to be an important issue in the understanding of its functions. DD1 DD2 ZnF-UBP Early investigations considering mouse HDAC6 showed that the protein is actively retained in the cytoplasm and Nuclear Cytoplasmic could, only under specific circumstances, be partially exclusion anchoring Catalytic activity found in the nucleus (Verdel et al., 2000). Indeed, a − α-tubulin strong nuclear export signal (NES) located N terminus - HSP90 Ubiquitin to the first catalytic domain prevents the accumulation binding of the protein in the nucleus (Figure 1). Interestingly, although this N-terminus NES is conserved in human Figure 1 Functional domain organization of HDAC6. HDAC6 is the only member of the histone deacetylase family containing HDAC6 (hHDAC6), another region of the protein was tandem catalytic domains. So far two in vivo substrates, a-tubulin found to ensure a stable anchorage of the protein in the and HSP90, have been identified. In human HDAC6, two different
Recommended publications
  • Mapping Influenza-Induced Posttranslational Modifications On
    viruses Article Mapping Influenza-Induced Posttranslational Modifications on Histones from CD8+ T Cells Svetlana Rezinciuc 1, Zhixin Tian 2, Si Wu 2, Shawna Hengel 2, Ljiljana Pasa-Tolic 2 and Heather S. Smallwood 1,3,* 1 Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38163, USA; [email protected] 2 Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA 99354, USA; [email protected] (Z.T.); [email protected] (S.W.); [email protected] (S.H.); [email protected] (L.P.-T.) 3 Children’s Foundation Research Institute, Memphis, TN 38105, USA * Correspondence: [email protected]; Tel.: +1-(901)-448–3068 Academic Editor: Italo Tempera Received: 10 October 2020; Accepted: 2 December 2020; Published: 8 December 2020 Abstract: T cell function is determined by transcriptional networks that are regulated by epigenetic programming via posttranslational modifications (PTMs) to histone proteins and DNA. Bottom-up mass spectrometry (MS) can identify histone PTMs, whereas intact protein analysis by MS can detect species missed by bottom-up approaches. We used a novel approach of online two-dimensional liquid chromatography-tandem MS with high-resolution reversed-phase liquid chromatography (RPLC), alternating electron transfer dissociation (ETD) and collision-induced dissociation (CID) on precursor ions to maximize fragmentation of uniquely modified species. The first online RPLC separation sorted histone families, then RPLC or weak cation exchange hydrophilic interaction liquid chromatography (WCX-HILIC) separated species heavily clad in PTMs. Tentative identifications were assigned by matching proteoform masses to predicted theoretical masses that were verified with tandem MS. We used this innovative approach for histone-intact protein PTM mapping (HiPTMap) to identify and quantify proteoforms purified from CD8 T cells after in vivo influenza infection.
    [Show full text]
  • Nitric Oxide Mediated Redox Regulation of Protein Homeostasis T Irmgard Tegeder
    Cellular Signalling 53 (2019) 348–356 Contents lists available at ScienceDirect Cellular Signalling journal homepage: www.elsevier.com/locate/cellsig Nitric oxide mediated redox regulation of protein homeostasis T Irmgard Tegeder Institute of Clinical Pharmacology, Goethe University Hospital Frankfurt, Theodor Stern Kai 7, 60590 Frankfurt, Germany ARTICLE INFO ABSTRACT Keywords: Nitric oxide is a versatile diffusible signaling molecule, whose biosynthesis by three NO synthases (NOS) is tightly regulated Nitric oxide at transcriptional and posttranslational levels, availability of co-factors, and calcium binding. Above normal levels of NO Chaperone have beneficial protective effects for example in the cardiovascular system, but also contribute to the pathophysiology inthe Ubiquitin context of inflammatory diseases, and to aging and neurodegeneration in the nervous system. The effect specificity relieson Aging the functional and spatial specificity of the NOS isoenzymes, and on the duality of two major signaling mechanisms (i) Proteostasis activation of soluble guanylycylase (sGC)-dependent cGMP production and (ii) direct S-nitrosylation of redox sensitive cy- Nitrosylation steines of susceptible proteins. The present review summarizes the functional implications of S-nitrosylation in the context of proteostasis, and focuses on two NO target proteins, heat shock cognate of 70 kDa (Hsc70/HSPA8) and the ubiquitin 2 ligase (UBE2D), because both are modified on functionally critical cysteines and are key regulators of chaperone mediated and assisted autophagy and proteasomal protein degradation. SNO modifications of these candidates are associated with protein accumulations and adoption of a senescent phenotype of neuronal cells suggesting that S-nitrosylations of protein homeo- static machineries contribute to aging phenomena. 1. Introduction PKG1, [15] leading to smooth muscle relaxation via regulation of intracellular calcium stores [16] and actin-myosin dynamics.
    [Show full text]
  • An Overview of the Role of Hdacs in Cancer Immunotherapy
    International Journal of Molecular Sciences Review Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy Debarati Banik, Sara Moufarrij and Alejandro Villagra * Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, 800 22nd St NW, Suite 8880, Washington, DC 20052, USA; [email protected] (D.B.); [email protected] (S.M.) * Correspondence: [email protected]; Tel.: +(202)-994-9547 Received: 22 March 2019; Accepted: 28 April 2019; Published: 7 May 2019 Abstract: Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors (HDACis) have positioned these agents as promising drug candidates in combatting cancer, autoimmune, neurodegenerative, and infectious diseases. The same has also encouraged the evaluation of multiple HDACi candidates in preclinical studies in cancer and other diseases as well as the FDA-approval towards clinical use for specific agents. In this review, we have discussed how the efficacy of immunotherapy can be leveraged by combining it with HDACis. We have also included a brief overview of the classification of HDACis as well as their various roles in physiological and pathophysiological scenarios to target key cellular processes promoting the initiation, establishment, and progression of cancer. Given the critical role of the tumor microenvironment (TME) towards the outcome of anticancer therapies, we have also discussed the effect of HDACis on different components of the TME. We then have gradually progressed into examples of specific pan-HDACis, class I HDACi, and selective HDACis that either have been incorporated into clinical trials or show promising preclinical effects for future consideration.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Determining HDAC8 Substrate Specificity by Noah Ariel Wolfson A
    Determining HDAC8 substrate specificity by Noah Ariel Wolfson A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Biological Chemistry) in the University of Michigan 2014 Doctoral Committee: Professor Carol A. Fierke, Chair Professor Robert S. Fuller Professor Anna K. Mapp Associate Professor Patrick J. O’Brien Associate Professor Raymond C. Trievel Dedication My thesis is dedicated to all my family, mentors, and friends who made getting to this point possible. ii Table of Contents Dedication ....................................................................................................................................... ii List of Figures .............................................................................................................................. viii List of Tables .................................................................................................................................. x List of Appendices ......................................................................................................................... xi Abstract ......................................................................................................................................... xii Chapter 1 HDAC8 substrates: Histones and beyond ...................................................................... 1 Overview ..................................................................................................................................... 1 HDAC introduction
    [Show full text]
  • Transcriptional Analysis of Sodium Valproate in a Serotonergic Cell Line Reveals Gene Regulation Through Both HDAC Inhibition-Dependent and Independent Mechanisms
    bioRxiv preprint doi: https://doi.org/10.1101/837732; this version posted November 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Transcriptional analysis of sodium valproate in a serotonergic cell line reveals gene regulation through both HDAC inhibition-dependent and independent mechanisms Priyanka Sinha1,2, Simone Cree1,2, Allison L. Miller1,2, John F. Pearson1,2,3, Martin A. Kennedy1,2. 1Gene Structure and Function Laboratory, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand. 2Carney Centre for Pharmacogenomics, University of Otago, Christchurch, New Zealand. 3Biostatistics and Computational Biology Unit, University of Otago, Christchurch, New Zealand. Correspondence to: Prof. M. A. Kennedy Department of Pathology and Biomedical Science University of Otago, Christchurch Christchurch, New Zealand Email: [email protected] Keywords: RNA-Seq, NanoString, lithium, valproate, HDAC inhibitor, mood stabilizer 1 bioRxiv preprint doi: https://doi.org/10.1101/837732; this version posted November 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Sodium valproate (VPA) is a histone deacetylase (HDAC) inhibitor, widely prescribed in the treatment of bipolar disorder, and yet the precise modes of therapeutic action for this drug are not fully understood.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Molecular Interactions Underpinning the Phenotype of Hibernation in Mammals Matthew T
    © 2019. Published by The Company of Biologists Ltd | Journal of Experimental Biology (2019) 222, jeb160606. doi:10.1242/jeb.160606 REVIEW Molecular interactions underpinning the phenotype of hibernation in mammals Matthew T. Andrews* ABSTRACT most mammals. This Review covers recent advances in the Mammals maintain a constant warm body temperature, facilitating a molecular biology of hibernation, with a focus on molecular wide variety of metabolic reactions. Mammals that hibernate have the interactions underpinning the hibernation phenotype. Specific – ability to slow their metabolism, which in turn reduces their body topics include the torpor arousal cycle, the role of small temperature and leads to a state of hypothermic torpor. For this molecules, changes in gene expression, cold-inducible RNA- metabolic rate reduction to occur on a whole-body scale, molecular binding proteins, the somatosensory system and emerging interactions that change the physiology of cells, tissues and organs information on hibernating primates. This new information not are required, resulting in a major departure from normal mammalian only is beginning to explain how natural hibernators survive homeostasis. The aim of this Review is to cover recent advances in the physiological extremes that would be lethal to most mammals, but molecular biology of mammalian hibernation, including the role of also identifies molecular mechanisms that may prove useful to small molecules, seasonal changes in gene expression, cold- human medicine. inducible RNA-binding proteins,
    [Show full text]
  • Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: an Update
    biomedicines Review Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update Sonja Vukadin 1,2, Farah Khaznadar 1, Tomislav Kizivat 3,4, Aleksandar Vcev 5,6,7 and Martina Smolic 1,2,* 1 Department of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia; [email protected] (S.V.); [email protected] (F.K.) 2 Department of Pharmacology, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia 3 Clinical Institute of Nuclear Medicine and Radiation Protection, University Hospital Osijek, 31000 Osijek, Croatia; [email protected] 4 Department of Nuclear Medicine and Oncology, Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia 5 Department of Pathophysiology, Physiology and Immunology, Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia; [email protected] 6 Department of Pathophysiology, Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia 7 Department of Internal Medicine, University Hospital Osijek, 31000 Osijek, Croatia * Correspondence: [email protected] Abstract: Over the past decade, immune checkpoint inhibitors (ICI) have revolutionized the treatment of advanced melanoma and ensured significant improvement in overall survival versus chemother- apy. ICI or targeted therapy are now the first line treatment in advanced melanoma, depending on the tumor v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutational status. While these Citation: Vukadin, S.; Khaznadar, F.; new approaches have changed the outcomes for many patients, a significant proportion of them still Kizivat, T.; Vcev, A.; Smolic, M.
    [Show full text]
  • Valproate Protective Effects on Cisplatin-Induced Peripheral Neuropathy: an in Vitro and in Vivo Study
    ANTICANCER RESEARCH 28: 335-342 (2008) Valproate Protective Effects on Cisplatin-induced Peripheral Neuropathy: An In Vitro and In Vivo Study VIRGINIA RODRIGUEZ-MENENDEZ, ALESSANDRA GILARDINI, MARIO BOSSI, ANNALISA CANTA, NORBERTO OGGIONI, VALENTINA CAROZZI, LUCIO TREMOLIZZO and GUIDO CAVALETTI Department of Neurosciences and Biomedical Technologies, University of Milano-Bicocca, Monza (MI), Italy Abstract. Background: Antineoplastic drugs, such as cisplatin and cisplatin animal models, without interfering with the (CDDP), induce disabling peripheral neuropathies, antitumoral activity of the antineoplastic drugs (6). ALC is representing a hindrance to effective cancer treatments. The a member of the family of carnitines, a naturally occurring exact pathogenesis of CDDP-induced neuropathy is not yet compound that has an essential role in intermediary understood, and the dysregulation of gene expression has been metabolism (7, 8). Recently, some clinical studies on proposed. Valproate (VPA) is an antiepileptic drug recently patients with neuropathies of different origin such as discovered to remodel gene expression, with hypothetically chronic diabetes, antiretroviral toxic neuropathy or putative neuroprotective effects. Materials and Methods: VPA paclitaxel- and cisplatin-induced peripheral neuropathies was tested in both, in vitro and in vivo models of CDDP- have seemed to confirm the neuroprotective action of ALC neurotoxicity. Results: VPA administered in combination with suggested by the animal model experimental data (9-11). In CDDP promoted dorsal root ganglia (DRG) neurons survival. fact, several results from different experimental paradigms Moreover, this treatment induced in Wistar rats an have suggested that ALC treatment promotes peripheral improvement of body weight, sensory nerve conduction nerve regeneration and has neuroprotective activity (11-14). velocity, and DRG morphometric analysis.
    [Show full text]
  • Supp Table 6.Pdf
    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
    [Show full text]
  • Design and Synthesis of Novel Classes of Hdacs and Kmts Inhibitors
    University of East Anglia School of Pharmacy Design and synthesis of novel classes of HDACs and KMTs inhibitors by Remy Thomas Narozny Supervisor: Prof. A. Ganesan Second Supervisor: Prof. Mark Searcey Thesis for the degree of Doctor of Philosophy November 2018 This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with the author and that use of any information derived therefrom must be in accordance with current UK Copyright Law. In addition, any quotation or extract must include full attribution. “Your genetics is not your destiny.” George McDonald Church Abstract For long, scientists thought that our body was driven only by our genetic code that we inherited at birth. However, this determinism was shattered entirely and proven as false in the second half of the 21st century with the discovery of epigenetics. Instead, cells turn genes on and off using reversible chemical marks. With the tremendous progression of epigenetic science, it is now believed that we have a certain power over the expression of our genetic traits. Over the years, these epigenetic modifications were found to be at the core of how diseases alter healthy cells, and environmental factors and lifestyle were identified as top influencers. Epigenetic dysregulation has been observed in every major domain of medicine, with a reported implication in cancer development, neurodegenerative pathologies, diabetes, infectious disease and even obesity. Substantially, an epigenetic component is expected to be involved in every human disease. Hence, the modulation of these epigenetics mechanisms has emerged as a therapeutic strategy.
    [Show full text]